These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 7979464)

  • 1. Surfactant phosphatidylcholine composition during dexamethasone treatment in chronic lung disease.
    Ashton MR; Postle AD; Smith DE; Hall MA
    Arch Dis Child Fetal Neonatal Ed; 1994 Sep; 71(2):F114-7. PubMed ID: 7979464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Turnover of exogenous artificial surfactant.
    Ashton MR; Postle AD; Hall MA; Austin NC; Smith DE; Normand IC
    Arch Dis Child; 1992 Apr; 67(4 Spec No):383-7. PubMed ID: 1586175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphatidylcholine composition of endotracheal tube aspirates of neonates and subsequent respiratory disease.
    Ashton MR; Postle AD; Hall MA; Smith SL; Kelly FJ; Normand IC
    Arch Dis Child; 1992 Apr; 67(4 Spec No):378-82. PubMed ID: 1586174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized, controlled trial.
    Durand M; Sardesai S; McEvoy C
    Pediatrics; 1995 Apr; 95(4):584-90. PubMed ID: 7700763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants.
    Rastogi A; Akintorin SM; Bez ML; Morales P; Pildes RS
    Pediatrics; 1996 Aug; 98(2 Pt 1):204-10. PubMed ID: 8692619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multicenter study.
    Kari MA; Hallman M; Eronen M; Teramo K; Virtanen M; Koivisto M; Ikonen RS
    Pediatrics; 1994 May; 93(5):730-6. PubMed ID: 8165070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexamethasone therapy in preterm infants developing bronchopulmonary dysplasia: effect on pulmonary surfactant disaturated-phosphatidylcholine kinetics.
    Cogo PE; Simonato M; Mariatoffolo G; Stefanutti G; Chierici M; Cobelli C; Ori C; Carnielli VP
    Pediatr Res; 2008 Apr; 63(4):433-7. PubMed ID: 18356753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late (> 7 days) postnatal corticosteroids for chronic lung disease in preterm infants.
    Doyle LW; Ehrenkranz RA; Halliday HL
    Cochrane Database Syst Rev; 2014 May; (5):CD001145. PubMed ID: 24825542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone treatment of infants at risk for chronic lung disease: surfactant components and inflammatory parameters in airway specimens.
    Kari MA; Raivio KO; Venge P; Hallman M
    Pediatr Res; 1994 Sep; 36(3):387-93. PubMed ID: 7808837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled versus systemic corticosteroids for the treatment of chronic lung disease in ventilated very low birth weight preterm infants.
    Shah SS; Ohlsson A; Halliday H; Shah VS
    Cochrane Database Syst Rev; 2003; (2):CD002057. PubMed ID: 12804423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse effects of early dexamethasone treatment in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
    Stark AR; Carlo WA; Tyson JE; Papile LA; Wright LL; Shankaran S; Donovan EF; Oh W; Bauer CR; Saha S; Poole WK; Stoll BJ;
    N Engl J Med; 2001 Jan; 344(2):95-101. PubMed ID: 11150359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of dexamethasone on respirator-dependent very-low-birth-weight infants is best predicted by chest X-ray.
    Schrod L; Neuhaus T; Horwitz AE; Speer CP
    Pediatr Radiol; 2001 May; 31(5):332-8. PubMed ID: 11373920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates.
    Shah SS; Ohlsson A; Halliday H; Shah VS
    Cochrane Database Syst Rev; 2003; (1):CD002058. PubMed ID: 12535425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early surfactant administration with brief ventilation vs selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS.
    Stevens TP; Blennow M; Soll RF
    Cochrane Database Syst Rev; 2002; (2):CD003063. PubMed ID: 12076469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.
    Doyle LW; Ehrenkranz RA; Halliday HL
    Cochrane Database Syst Rev; 2014 May; (5):CD001146. PubMed ID: 24825456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome.
    Wang JY; Yeh TF; Lin YC; Miyamura K; Holmskov U; Reid KB
    Thorax; 1996 Sep; 51(9):907-13. PubMed ID: 8984701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized controlled trial of three different doses of aerosol beclomethasone versus systemic dexamethasone to promote extubation in ventilated premature infants.
    Rozycki HJ; Byron PR; Elliott GR; Carroll T; Gutcher GR
    Pediatr Pulmonol; 2003 May; 35(5):375-83. PubMed ID: 12687595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants.
    Halliday HL; Ehrenkranz RA
    Cochrane Database Syst Rev; 2000; (2):CD001146. PubMed ID: 10796252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant.
    Brozanski BS; Jones JG; Gilmour CH; Balsan MJ; Vazquez RL; Israel BA; Newman B; Mimouni FB; Guthrie RD
    J Pediatr; 1995 May; 126(5 Pt 1):769-76. PubMed ID: 7752005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementing potentially better practices to improve neonatal outcomes after reducing postnatal dexamethasone use in infants born between 501 and 1250 grams.
    Kaempf JW; Campbell B; Sklar RS; Arduza C; Gallegos R; Zabari M; Brown A; McDonald JV
    Pediatrics; 2003 Apr; 111(4 Pt 2):e534-41. PubMed ID: 12671173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.